

Lionis, Christos

University of Crete



Christos Lionis is a medical doctor and Professor with a distinguished career in primary care and public health education, practice, and research. Since March 1995, he has served at the Clinic of Social and Family Medicine (CSFM), School of Medicine, University of Crete, as Professor of General Practice and Primary Health Care and Director of CSFM until August 2022. In January 2023, he was appointed Professor Emeritus of the University of Crete.

He was also serving as Guest Professor of General Practice at the Institute of Health and Medicine, University of Linköping, Sweden (since 2018), and in December 2024 was elected Professor of Primary Health Care and Public Health at the School of Medicine, University of Limassol, Cyprus.

As Principal Investigator and collaborator, Professor Lionis has contributed to numerous large-scale European and international research initiatives funded by the EU and other global agencies, focusing on capacity building in primary health care and public health in Greece and worldwide. Passionate about education, he has been instrumental in advancing medical training, continuing medical education, and quality standards in primary care and public health nationally.

He serves in editorial and advisory roles for several international journals and on executive boards of professional organisations, including as Chair of the WONCA Working Party on Mental Health. His professional distinctions include being awarded Honorary Fellowship by the Royal College of General Practitioners (2009), the World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians – WONCA (2016), and the European Society of Cardiology (2017).

Professor Lionis has published 479 papers indexed in PubMed, with an h-index of 70, i10 index of 354, and 47,667 citations (AD Scientific Index, 26 August 2025).

He has also served as a member of the European Commission Expert Panel on Effective Ways of Investing in Health (2019–2022), the Specific Advisory Group of the European Medicines Agency (until 2024), and the National Committee for Mental Health Reform and Bioethics and Biotechnology

(since 2022).